|
1
|
Post-traumatic endophthalmitis.
|
Ophthalmology
|
2004
|
2.53
|
|
2
|
Cancer and the microenvironment: myeloma-osteoclast interactions as a model.
|
Cancer Res
|
2004
|
1.98
|
|
3
|
Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.
|
Cancer
|
2008
|
1.82
|
|
4
|
Th9 cells promote antitumor immune responses in vivo.
|
J Clin Invest
|
2012
|
1.80
|
|
5
|
Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma.
|
Nat Genet
|
2012
|
1.64
|
|
6
|
Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma.
|
Blood
|
2009
|
1.61
|
|
7
|
Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies.
|
Cancer Cell
|
2006
|
1.58
|
|
8
|
Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis.
|
Blood
|
2009
|
1.58
|
|
9
|
Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.
|
Am J Hematol
|
2009
|
1.57
|
|
10
|
Triggering of toll-like receptor-4 in human multiple myeloma cells promotes proliferation and alters cell responses to immune and chemotherapy drug attack.
|
Cancer Biol Ther
|
2011
|
1.50
|
|
11
|
Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis.
|
Cancer Cell
|
2007
|
1.45
|
|
12
|
Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells.
|
Blood
|
2006
|
1.30
|
|
13
|
A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma.
|
Clin Cancer Res
|
2008
|
1.29
|
|
14
|
Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma.
|
Blood
|
2007
|
1.26
|
|
15
|
Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy.
|
Blood
|
2002
|
1.23
|
|
16
|
Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells.
|
Blood
|
2010
|
1.23
|
|
17
|
Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma.
|
Blood
|
2005
|
1.21
|
|
18
|
Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo.
|
Leuk Res
|
2010
|
1.13
|
|
19
|
Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts.
|
Blood
|
2007
|
1.12
|
|
20
|
Critical roles of Raf/MEK/ERK and PI3K/AKT signaling and inactivation of p38 MAP kinase in the differentiation and survival of monocyte-derived immature dendritic cells.
|
Exp Hematol
|
2005
|
1.12
|
|
21
|
Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone.
|
J Mol Med (Berl)
|
2011
|
1.10
|
|
22
|
Nuclear export of NF90 to stabilize IL-2 mRNA is mediated by AKT-dependent phosphorylation at Ser647 in response to CD28 costimulation.
|
J Immunol
|
2008
|
1.09
|
|
23
|
Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.
|
Clin Cancer Res
|
2005
|
1.08
|
|
24
|
Effect of long-term storage in TRIzol on microarray-based gene expression profiling.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
1.04
|
|
25
|
Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells.
|
Blood
|
2012
|
1.03
|
|
26
|
Novel and detrimental effects of lipopolysaccharide on in vitro generation of immature dendritic cells: involvement of mitogen-activated protein kinase p38.
|
J Immunol
|
2003
|
1.03
|
|
27
|
p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction.
|
Cancer Res
|
2012
|
1.02
|
|
28
|
Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells.
|
Blood
|
2003
|
1.02
|
|
29
|
Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma.
|
Blood
|
2011
|
1.01
|
|
30
|
Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers.
|
Proc Natl Acad Sci U S A
|
2014
|
1.00
|
|
31
|
Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens.
|
Haematologica
|
2011
|
0.99
|
|
32
|
Zinc finger transcription factor 191, directly binding to β-catenin promoter, promotes cell proliferation of hepatocellular carcinoma.
|
Hepatology
|
2012
|
0.97
|
|
33
|
Utilizing TH9 cells as a novel therapeutic strategy for malignancies.
|
Oncoimmunology
|
2013
|
0.95
|
|
34
|
Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways.
|
Blood
|
2007
|
0.95
|
|
35
|
Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth.
|
Cancer Res
|
2008
|
0.94
|
|
36
|
Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma.
|
Clin Cancer Res
|
2009
|
0.92
|
|
37
|
Toll-like receptor-4 signaling in mantle cell lymphoma: effects on tumor growth and immune evasion.
|
Cancer
|
2012
|
0.92
|
|
38
|
HDGF-related protein-3 is required for anchorage-independent survival and chemoresistance in hepatocellular carcinomas.
|
Gut
|
2012
|
0.92
|
|
39
|
IL-2 mRNA stabilization upon PMA stimulation is dependent on NF90-Ser647 phosphorylation by protein kinase CbetaI.
|
J Immunol
|
2010
|
0.90
|
|
40
|
Lamellipodium extension and membrane ruffling require different SNARE-mediated trafficking pathways.
|
BMC Cell Biol
|
2010
|
0.89
|
|
41
|
Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives.
|
Am J Blood Res
|
2011
|
0.88
|
|
42
|
Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma.
|
Front Biosci
|
2007
|
0.88
|
|
43
|
In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome.
|
Mol Cancer Ther
|
2013
|
0.86
|
|
44
|
Beta2-microglobulin as a potential initiator of inflammatory responses.
|
Trends Immunol
|
2003
|
0.85
|
|
45
|
Multiple myeloma, painful neuropathy, acupuncture?
|
Am J Clin Oncol
|
2009
|
0.85
|
|
46
|
CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma.
|
Cancer Immunol Immunother
|
2011
|
0.84
|
|
47
|
Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes.
|
Clin Cancer Res
|
2011
|
0.84
|
|
48
|
Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells.
|
Haematologica
|
2013
|
0.83
|
|
49
|
Targeting cell surface β2 -microglobulin by pentameric IgM antibodies.
|
Br J Haematol
|
2011
|
0.82
|
|
50
|
p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion.
|
Int J Cancer
|
2014
|
0.82
|
|
51
|
Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
|
Am J Hematol
|
2008
|
0.81
|
|
52
|
Molecular mechanism of monodisperse colloidal tin-doped indium oxide nanocrystals by a hot-injection approach.
|
Nanoscale Res Lett
|
2013
|
0.81
|
|
53
|
Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.
|
Int J Cancer
|
2014
|
0.81
|
|
54
|
Beta(2)-microglobulin as a negative growth regulator of myeloma cells.
|
Br J Haematol
|
2002
|
0.80
|
|
55
|
Effects of Misspecifying the First-Level Error Structure in Two-Level Models of Change.
|
Multivariate Behav Res
|
2002
|
0.79
|
|
56
|
Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules.
|
Cancer
|
2010
|
0.79
|
|
57
|
Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression.
|
PLoS One
|
2013
|
0.78
|
|
58
|
Human osteoclasts are inducible immunosuppressive cells in response to T cell-derived IFN-γ and CD40 ligand in vitro.
|
J Bone Miner Res
|
2014
|
0.78
|
|
59
|
Delivery of photocoagulation treatment for diabetic retinopathy at a large Australian ophthalmic hospital: comparisons with national clinical practice guidelines.
|
Clin Experiment Ophthalmol
|
2002
|
0.78
|
|
60
|
Murine Th9 cells promote the survival of myeloid dendritic cells in cancer immunotherapy.
|
Cancer Immunol Immunother
|
2014
|
0.78
|
|
61
|
Synthesis of unstable colloidal inorganic nanocrystals through the introduction of a protecting ligand.
|
Nano Lett
|
2014
|
0.78
|
|
62
|
DKK1 as a novel target for myeloma immunotherapy.
|
Oncoimmunology
|
2012
|
0.77
|
|
63
|
Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma.
|
Br J Haematol
|
2014
|
0.77
|
|
64
|
Monocyte-derived dendritic cells: a promising armament for immunotherapy in human malignancies.
|
Clin Cancer Res
|
2005
|
0.75
|
|
65
|
[Study on risk awareness and preparedness for pandemic flu among staff members from enterprises].
|
Zhonghua Liu Xing Bing Xue Za Zhi
|
2007
|
0.75
|
|
66
|
The impact of data collection design, linking method, and sample size on vertical scaling using the Rasch model.
|
J Appl Meas
|
2008
|
0.75
|
|
67
|
American Journal of Blood Research: Editorial Board (2011) e-Century Publishing Corporation.
|
Am J Blood Res
|
2011
|
0.75
|
|
68
|
Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.
|
Leuk Res
|
2011
|
0.75
|
|
69
|
[Therapeutic efficacy of chemotherapy combined with radiotherapy in 527 patients with stage III and IV non-small cell lung cancer].
|
Zhongguo Fei Ai Za Zhi
|
2007
|
0.75
|
|
70
|
Erratum. PD-L1-Driven Tolerance Protects Neurogenin3-Induced Islet Neogenesis to Reverse Established Type 1 Diabetes in NOD Mice. Diabetes 2015;64:529-540.
|
Diabetes
|
2015
|
0.75
|
|
71
|
Transforming and secreting expression of human egf in mutant strain WYBS2001 of Bacillus and its functions.
|
Yi Chuan Xue Bao
|
2003
|
0.75
|
|
72
|
Strategic consideration on treatment of multiple myeloma.
|
Chin Med J (Engl)
|
2011
|
0.75
|
|
73
|
Launching of american journal of blood research.
|
Am J Blood Res
|
2011
|
0.75
|
|
74
|
Immunotherapy for multiple myeloma.
|
Clin Dev Immunol
|
2012
|
0.75
|
|
75
|
Comparing single-pool and multiple-pool designs regarding test security in computerized testing.
|
Behav Res Methods
|
2012
|
0.75
|
|
76
|
[Impacts of rice straw biochar on organic carbon and CO2 release in arable soil].
|
Huan Jing Ke Xue
|
2014
|
0.75
|